Table 1

Demographic and clinical features of enrolled individuals

	Patients with SLE	Controls	P
n	50	50
Age in years, median (IQR)	44 (36–58)	45 (31–55)	0.446*
Gender (M/F), n	2/48	2/48
SLEDAI-2K, median (range)	2 (0–13)	N/A
ANAs titres when diagnosed,† median (IQR)	1:640 (1:320–1:1280)	N/A
Corticosteroid use, n (%)	29 (58%)	N/A
Hydroxychloroquine use, n (%)	31 (62%)	N/A
Statin use, n (%)	10 (20%)	N/A
Months since the diagnostic, median (IQR)	72 (36–132)	N/A
Family history of autoimmune diseases, n (%)	21 (42%)	N/A
Comorbidities, n (%)	37 (74%)	N/A

*Mann-Whitney U test.
†Data available for 40 donors.
ANAs, antinuclear antibodies; N/A, not applicable; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000.